Professor Syed Hussain
MBBS, MSc, MD, FRCP
Clinical Medicine, School of Medicine and Population Health
Professor of Medical Oncology
+44 114 215 9682
Full contact details
Clinical Medicine, School of Medicine and Population Health
Room 228, 2nd Floor, Broomcross Building
Weston Park Hospital
Whitham Road
葫芦影业
S10 2SJ
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
Professor Hussain graduated from Dow Medical College Karachi in 1994. He completed his general medical professional training in UK. He did his Doctorate in Oncology from University of Birmingham. He completed his medical oncology training in Birmingham, United Kingdom and received his certification and specialist registration in medical oncology.
Professor Hussain is Professor and Honorary Consultant in Medical Oncology at the University of 葫芦影业 and 葫芦影业 Teaching Hospitals NHS Trust. His major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. He has set up several clinical trials from early phase to late phase studies during his career. His work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001) to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012). This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment globally. He has tailored split dose cisplatin regimen that has led to expand the spectrum of patients receiving cisplatin-based chemotherapy in bladder cancer (Hussain et al BJC 2004). He is a principal investigator of several studies in urological cancers. He was chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study (NEOBLADE) in muscle invasive bladder cancer. He has served as a chief investigator of various early phase clinical trials, and translational studies. He is a chief investigator of a first in human window of opportunity study (INVEST) investigating the role of intravesical/intratumoral atezolizumab in patients with bladder cancer undergoing curative cystectomy. This is sponsored by STH and funded by Roche. He is also chief investigator of an international window of opportunity trial SOGUG NEOWIN investigating the role of erdafitinib and cetrelimab in FGF mutant bladder cancer patients undergoing curative cystectomy. This is jointly led by Hussain (UK), with Andrea Necchi (Italy), Yohann Loriot (France) and Guillermo Velasco (Spain) as other co-chief investigators. This study is funded by Janssen. He has authored over 125 peer-reviewed publications including 4 book chapters in textbooks of oncology. His Google scholar H-index is 40 with over 9800 citations (April 2023). He has published in high impact journals including New England Journal of Medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, European Urology, Annals of Oncology, Nature Communications, Clinical Cancer Research, British Journal of Cancer. He has been an invited speaker to number of national and international meetings and have delivered over 110 invited lectures. He has secured funding from cancer charities, national funding bodies and industries of over 拢15 million.
Professor Hussain was the member of NCRI Bladder and Renal group and Chair of the NCRI- Advanced Bladder Cancer sub-group in his national role. Professor Hussain was the expert witness to NICE on successful technology appraisals of Atezolizumab (2017), Avelumab (2021) and Nivolumab in Bladder cancer (2022).
- Research interests
-
My major areas of interest are management of urological cancers, clinical trials, early drug development and translational medicine. I have set up a large number of clinical trials from early phase to late phase studies during my career.
My work on organ preservation in bladder cancer moved all the way from an early phase I study (Hussain et al Annals of Oncology 2001), to phase II efficacy study (Hussain et al BJC 2004) that led to a Cancer Research UK funded study BC2001 trial that was reported in New England Journal of Medicine (James, Hussain, Hall et al April 2012).
This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment. I am principal investigator of a number of studies in urological cancers.
I am chief investigator of a national randomised placebo-controlled phase II neo-adjuvant study in muscle invasive bladder cancer and have served as chief investigator of various early phase trials, and translational studies.
I have authored over 125 peer-reviewed publications including 4 book chapters in textbooks of oncology. My Google scholar H-index is 40 with over 9800 citations (April 2023). I have published in high impact journals including New England Journal of Medicine, Lancet, Lancet Oncology, JAMA, JAMA Oncology, Journal of Clinical Oncology, European Urology, Annals of Oncology, Nature Communications, Clinical Cancer Research, British Journal of Cancer. I have been an invited speaker at a number of national and international meetings and have delivered over 110 invited lectures. I have secured funding from cancer charities, national funding bodies and industries of over 拢15 million.
Current Projects
- Setting up of clinical trials in bladder cancers.
- Early phase studies in bladder cancer.
- Development of panel of Biomarkers in bladder cancer.
- Translational research linked to bladder cancer clinical trials.
- Publications
-
Show: Featured publications All publications
Featured publications
This person does not have any publications available.
All publications
Journal articles
- . BJU International.
- . Annals of Oncology, 35, S1163-S1164.
- . Cureus, 16(8), e66520.
- . Urologic Oncology: Seminars and Original Investigations.
- . Journal of Clinical Oncology, 42(16_suppl), TPS4621-TPS4621.
- . Journal of Clinical Oncology, 42(16_suppl), TPS4623-TPS4623.
- . Journal of Clinical Oncology, 42(16_suppl), e16619-e16619.
- . Journal of Clinical Oncology, 42(16_suppl), 4591-4591.
- . Urologic Oncology: Seminars and Original Investigations, 42, S53-S53.
- . Urologic Oncology: Seminars and Original Investigations, 42, S58-S58.
- . European Urology, 85, S427-S427.
- . eBioMedicine, 101, 105032-105032.
- . Journal of Clinical Oncology, 42(4_suppl), 584-584.
- . Journal of Clinical Oncology, 42(4_suppl), tps710-tps710.
- . Journal of Clinical Oncology, 42(4_suppl), 586-586.
- . The Journal of Pathology: Clinical Research, 10(2).
- . Annals of Oncology, 35(1), 98-106.
- . Annals of Oncology, 34, S1201-S1202.
- . Annals of Oncology, 34, S1341-S1342.
- . Annals of Oncology, 34, S1224-S1225.
- . Journal of Clinical Oncology, 41(16_suppl), 5088-5088.
- . European Urology.
- . Cancer Research, 83(8_Supplement), CT119-CT119.
- . Journal of Urology, 209(Supplement 4).
- . Journal of Clinical Oncology, 41(6_suppl), 531-531.
- . Journal of Clinical Oncology, 41(6_suppl), 193-193.
- . Journal of Clinical Oncology, 41(6_suppl), 504-504.
- . European Urology, 83, S219-S220.
- . BJU International.
- Re: Predictive Biomarkers for Survival Benefit With Ramucirumab in Urothelial Cancer in the RANGE Trial Editorial Comment. JOURNAL OF UROLOGY, 209(1), 291-291.
- . Journal of Clinical Oncology, 41(1), 54-64.
- . BJUI Compass.
- . Annals of Oncology, 33, S1348-S1348.
- . Annals of Oncology, 33, S1193-S1193.
- . Annals of Oncology, 33, S1330-S1330.
- . Journal of Clinical Oncology, 40(17_suppl), lba4505-lba4505.
- . Gastrointestinal Endoscopy, 95(6), AB287-AB287.
- . Journal of Clinical Oncology, 40(16_suppl), 4594-4594.
- . BJU International, 129(6), 691-694.
- . JAMA.
- . Am J Med.
- . Bladder Cancer, 1-14.
- . The Lancet Oncology, 23(5), 650-658.
- . Nature Communications, 13.
- . JAMA Oncology, 8(4), 546-546.
- . Journal of Clinical Oncology, 40(6_suppl), 26-26.
- . Journal of Clinical Oncology, 40(6_suppl), 518-518.
- . Journal of Clinical Oncology, 40(6_suppl), 436-436.
- . Journal of Clinical Oncology, 40(6_suppl), 132-132.
- . Journal of Clinical Oncology, 40(6_suppl), 461-461.
- . European Urology, 81, S1125-S1125.
- . European Urology.
- . Gynecologic Oncology Reports, 38.
- . The American Journal of Gastroenterology, 116(1), s1079-s1080.
- . The American Journal of Gastroenterology, 116(1), s1002-s1002.
- . The American Journal of Gastroenterology, 116(1), s1008-s1008.
- . Molecular and Clinical Oncology, 15(4).
- . European Urology Focus.
- . The Lancet Oncology, 22(7), 931-945.
- . Eur Urol.
- . Journal of Clinical Oncology, 39(15_suppl), e24105-e24105.
- . Journal of Clinical Oncology, 39(15_suppl), 6549-6549.
- . Clinical Genitourinary Cancer.
- . European Urology.
- . Journal of Clinical Oncology, 39(6_suppl), 440-440.
- . European Urology.
- . British Journal of Cancer.
- . European Urology, 79(2), 307-315.
- . The Lancet Oncology, 21(12), 1574-1588.
- . European Urology.
- Occupational Bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. PLoS ONE.
- . European Urology Oncology, 3(5), 671-679.
- . The American Journal of Gastroenterology, 115(1), s1628-s1628.
- . The American Journal of Gastroenterology, 115(1), s1475-s1475.
- . The American Journal of Gastroenterology, 115(1), s1240-s1240.
- . The American Journal of Gastroenterology, 115(1), s300-s300.
- . Jco Global Oncology, 6, 1248-1257.
- . Oncotarget, 11(31), 3025-3025.
- . European Urology Focus.
- . Trials, 21.
- . European Urology, 77(6), e156-e157.
- . Journal of Clinical Oncology, 38(6_suppl), 438-438.
- . Journal of Clinical Oncology, 38(6_suppl), 491-491.
- . Journal of Clinical Oncology, 38(6_suppl), 580-580.
- . European Urology, 77(2), 260-268.
- . Scientific Reports, 10(1).
- . The Lancet Oncology, 21(1), 105-120.
- . Annals of Oncology, 30, v373-v374.
- . The American Journal of Gastroenterology, 114(1), s1304-s1304.
- . American Journal of Gastroenterology, 114(1), S315-S315.
- . Annals of Allergy, Asthma & Immunology, 123(4), 375-380.e3.
- . European Urology, 76(5), 604-606.
- . European Urology, 76(3), 368-380.
- . Critical Reviews in Oncology and Hematology.
- . Journal of Clinical Oncology, 37(15_suppl), 5030-5030.
- . Journal of Clinical Oncology, 37(15_suppl), e16024-e16024.
- . Journal of Clinical Oncology, 37(15_suppl), 4543-4543.
- . Gastroenterology, 156(6), s-814-s-815.
- . European Urology, 75(3), e82-e83.
- . Journal of Clinical Oncology, 37(7_suppl), 432-432.
- . Clinical Cancer Research, 25(15), 4624-4633.
- . Annals of Oncology, 29(suppl_8), viii304-viii305.
- . The American Journal of Gastroenterology, 113(Supplement), s1553.
- . The American Journal of Gastroenterology, 113(Supplement), s96.
- . European Urology Oncology, 1(6), 486-500.
- . Gastrointestinal Endoscopy, 87(6), ab381.
- . Journal of Clinical Oncology, 36(15_suppl), e15078-e15078.
- . Gastroenterology, 154(6), s-300-s-301.
- . European Urology, 73(3), 462-468.
- . Journal of Clinical Oncology, 36(6_suppl), 463-463.
- . The Lancet, 391(10122), 748-757.
- . Clinical Genitourinary Cancer, 16(1), e161-e167.
- . European Urology Focus, 4(6), 937-945.
- . The Lancet, 390(10109), 2266-2277.
- . Annals of Oncology, 28, v621.
- . Journal of Clinical Oncology, 35(16), 1770-1777.
- . Gastrointestinal Endoscopy, 85(5), ab645.
- . Pharmacology & Therapeutics, 172, 181-194.
- . OncoTargets and Therapy, 8(19), 31041-31056.
- . International journal of oncology, 50(4), 1147-1159.
- . Journal of Clinical Oncology, 35(6_suppl), 280-280.
- . Journal of Clinical Oncology, 35(6_suppl), 339-339.
- . Journal of Clinical Oncology, 35(6_suppl), 323-323.
- . Journal of Clinical Oncology, 35(6_suppl), 141-141.
- . European Journal of Cancer, 72, s186-s187.
- . British Journal of Cancer, 116(5), 649-657.
- . International journal of oncology, 50(3), 768-772.
- . Journal of Clinical Oncology, 35(1), 48-55.
- . Oncotarget, 7(50), 82783-82797.
- . Annals of Oncology, 27, vi270-vi270.
- . Annals of Oncology, 27, vi270.
- . Journal of Clinical Oncology, 34(25), 3005-3013.
- . Clinical Genitourinary Cancer, 14(4), 331-340.
- . BJU International.
- . Journal of Clinical Oncology, 34(15_suppl), 4521-4521.
- . Journal of Clinical Oncology, 34(15_suppl), e16520-e16520.
- PARP Inhibition in Prostate Cancer: A Promising Approach. Oncology, 30(5), 393-394.
- . JAMA Oncology, 2(4), 493-493.
- . Investigative Urology, 195(4), e654.
- . Current Treatment Options in Oncology, 17(3).
- . European Urology, 69(3), 450-456.
- . Oncotarget, 7(8), 9322-9339.
- . Journal of Clinical Oncology, 34(2_suppl), 430-430.
- . Journal of Clinical Oncology, 34(2_suppl), 396-396.
- . Journal of Clinical Oncology, 34(2_suppl), 355-355.
- . Journal of Clinical Oncology, 34(2_suppl), 422-422.
- The cell cycle regulator p27Kip1 is associated with urothelial bladder cancer invasion. International Journal of Clinical and Experimental Pathology, 9(10), 10515-10521.
- . New England Journal of Medicine, 373(18), 1697-1708.
- . European Journal of Cancer, 51, S518-S518.
- . European Journal of Cancer, 51, s523.
- . European Journal of Cancer, 51, s527-s528.
- . Cancer, 121(15), 2586-2593.
- . Saudi Journal of Gastroenterology, 21(4), 254-254.
- . Oncology Letters, 10(1), 3-10.
- . Journal of Clinical Oncology, 33(15_suppl), 4524-4524.
- . Journal of Clinical Oncology, 33(15_suppl), 4505-4505.
- . Clinical Genitourinary Cancer, 13(2), 178-184.
- . Journal of Clinical Oncology, 33(7_suppl), 352-352.
- Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer. Journal of Clinical Oncology, 33 (supplement; abstract TPS4574).
- . Cancer Chemotherapy and Pharmacology, 75(1), 87-95.
- . European Journal of Cancer, 50, 185.
- . Annals of Oncology, 25, iv302.
- . Annals of Oncology, 25, iv267.
- . Urologic Oncology: Seminars and Original Investigations, 32(6), 806-814.
- . Journal of Clinical Oncology, 32(15_suppl), tps4589-tps4589.
- . Journal of Clinical Oncology, 32(15_suppl), 4512-4512.
- . Therapeutic Advances in Gastroenterology, 7(1), 14-19.
- . Cancer Epidemiology Biomarkers & Prevention, 23(1), 144-153.
- . International Journal of Radiation Oncology*Biology*Physics, 87(2), 261-269.
- . The American Journal of Gastroenterology, 108, s628.
- . Clinical Genitourinary Cancer, 11(3), 316-320.
- . British Journal of Cancer, 109(4), 888-890.
- . Journal of Clinical Oncology, 31(18_suppl), LBA5000-LBA5000.
- . Journal of Clinical Oncology, 31(15_suppl), lba5000-lba5000.
- . Journal of Clinical Oncology, 31(15_suppl), 4518-4518.
- . Therapeutic Advances in Gastroenterology, 6(3), 193-198.
- . American Society of Clinical Oncology Educational Book, 33, 200-206.
- . Digestive Endoscopy, 24(6), 482-482.
- . Digestive Endoscopy, 24(3), 185-187.
- . New England Journal of Medicine, 366(16), 1477-1488.
- . Gastrointestinal Endoscopy, 75(4), ab481-ab482.
- . Gastroenterology Res, 5(2), 52-56.
- . Journal of Addiction Medicine, 6(1), 89-91.
- . Journal of Clinical Oncology, 30(5_suppl), 167-167.
- . Journal of Clinical Oncology, 30(5_suppl), 308-308.
- . Journal of Clinical Oncology, 30(4_suppl), 372-372.
- . Gut and Liver, 6(1), 136-138.
- . PROTEOMICS - Clinical Applications, 5(9-10), 493-503.
- . The American Journal of Gastroenterology, 106, s559.
- . The American Journal of Gastroenterology, 106, s377.
- Diagnosis of multifocal small bowel carcinoid with double balloon Enteroscopy. Practical Gastroenterology, 35(9), 60-63.
- . Gastrointestinal Endoscopy, 73(4), ab465.
- . Gut, 60(Suppl 1), a115.
- . Digestive Diseases and Sciences, 56(3), 786-791.
- . Anti-Cancer Agents in Medicinal Chemistry, 11(3), 296-306.
- Tumour biology of germ cell tumours. Hematology/Oncology Clinics of North America, 25, 457-471.
- . Hematology/Oncology Clinics of North America, 25(3), 457-471.
- . Oncology Reports, 24(5), 1121-1131.
- . International Journal of Radiation Oncology 鈥 Biology 鈥 Physics, 78(3), s2-s3.
- . The American Journal of Gastroenterology, 105, s198.
- . Journal of Clinical Oncology, 28(15_suppl), e15118-e15118.
- . Journal of Clinical Oncology, 28(15_suppl), 4517-4517.
- . Gastrointestinal Endoscopy, 71(5), ab157-ab158.
- . BJU International, 105(6), 784-788.
- . Anti-Cancer Agents in Medicinal Chemistry, 10(3), 225-235.
- . Hemodialysis International, 14(1), 152-152.
- Advances in chemotherapy in breast cancer.. Oncology Report, 24, 1121-1131.
- . Digestive Diseases and Sciences, 54(10), 2296-2297.
- . The American Journal of Gastroenterology, 104, s502.
- . The American Journal of Gastroenterology, 104, s401.
- . European Journal of Cancer Supplements, 7(2), 423-423.
- . Nephrology Dialysis Transplantation, 24(7), 2290-2290.
- . Anti-Cancer Agents in Medicinal Chemistry, 9(5), 569-575.
- . Journal of Clinical Oncology, 27(15_suppl), e16543-e16543.
- . Journal of Clinical Oncology, 27(15_suppl), e16539-e16539.
- . Hemodialysis International, 13(2), 205-214.
- Re-challenging with Docetaxel chemotherapy following relapse: Is this an effective treatment strategy. Prostate Cancer Forum, 5, 1-9.
- . Cases Journal, 2(1), 8526-8526.
- . Expert Review of Anticancer Therapy, 8(10), 1659-1673.
- . International Journal of Radiation Oncology 鈥 Biology 鈥 Physics, 72(1), s7.
- . Journal of Clinical Oncology, 26(15_suppl), 16539-16539.
- . Journal of Clinical Oncology, 26(15_suppl), 16066-16066.
- . Journal of Gastrointestinal Cancer, 39(1-4), 107-113.
- . Current Pharmacogenomics and Personalized Medicine, 6(1), 45-55.
- . Expert Review of Anticancer Therapy, 8(5), 771-784.
- . Journal of the American Society of Nephrology, 18(9), 2592-2599.
- . Journal of Clinical Oncology, 25(18_suppl), 15551-15551.
- . British Journal of Cancer, 96(8), 1310-1310.
- . British Journal of Cancer, 96(1), 104-109.
- . BioDrugs, 21(4), 215-224.
- . Current Signal Transduction Therapy, 2(1), 21-30.
- . The American Journal of Gastroenterology, 101, s90-s91.
- . Current Opinion in Organ Transplantation, 11(4), 413-417.
- . Transplantation, 82(1), 938-939.
- . Journal of Clinical Oncology, 24(18_suppl), 17048-17048.
- . Kidney International, 68(4), 1834-1839.
- . Journal of Clinical Oncology, 23(16_suppl), 7272-7272.
- . Hemodialysis International, 9(2), 147-152.
- . Seminars in Radiation Oncology, 15(1), 19-27.
- . Expert Opinion on Biological Therapy, 5(4), 507-523.
- . Expert Review of Anticancer Therapy, 5(6), 1095-1110.
- . Seminars in Radiation Oncology, 15(1), 3-9.
- . BJU International, 95(4), 485-490.
- . BJU International, 95(4), 491-496.
- Management of muscle invasive bladder cancer 鈥 can we improve the results of bladder preserving therapy?. Seminars in Radiation Oncology, 15(1), 19-27.
- . Expert Opinion on Investigational Drugs, 13(12), 1555-1568.
- . British Journal of Cancer, 91(5), 844-849.
- . Journal of Clinical Oncology, 22(14_suppl), 4585-4585.
- . Journal of Clinical Oncology, 22(14_suppl), 4585-4585.
- . British Journal of Cancer, 90(11), 2106-2111.
- . Expert Review of Anticancer Therapy, 4(5), 877-888.
- . Expert Review of Anticancer Therapy, 4(6), 1179-1195.
- CD40 expression in prostatic carcinomas. Oncology Reports: an international journal devoted to fundamental and applied research in oncology, 12(4), 679-682.
- Role of hypoxic marker CA IX in Transitional cell carcinoma of the bladder.. Oncology Reports: an international journal devoted to fundamental and applied research in oncology, 11(5), 1005-1010.
- Role of endocrine therapy in early breast cancer. Expert Review of Anticancer Therapy, 5, 877-888.
- Role of endocrine therapy in metastatic breast cancer.. Expert Review of Anticancer Therapy, 6, 1179-1195.
- . The Lancet Oncology, 4(8), 489-497.
- . Clinical Endocrinology, 58(2), 141-150.
- . British Journal of Cancer, 88(4), 586-592.
- . International Journal of Radiation Oncology*Biology*Physics, 55(1), 190-193.
- BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncology Reports, 10(3), 571-576.
- . Expert Review of Anticancer Therapy, 2(6), 641-651.
- . The Journal of Clinical Endocrinology & Metabolism, 87(9), 4238-4244.
- . Clinical Transplantation, 16(1), 43-47.
- . Annals of Oncology, 12(7), 929-935.
- . Annals of Oncology, 12(2), 245-248.
- Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clinical Cancer Research, 7(9), 2662-2668.
- . Annals of Oncology, 12(2), 161-172.
- Role of chemotherapy in anal tumours. GI Cancer, 3(3), 181-187.
- . Oncology Reports, 20(4).
- . Cancer Research Communications.
- . British Journal of Cancer.
- . British Journal of Cancer.
- . Disease Models & Mechanisms.
- . JAMA Oncology.
- . JAMA Oncology.
- . BJU International.
- . BJU International.
- . BJU International.
- . Expert Opinion on Investigational Drugs.
- . Clinical Cancer Research.
- . Biomedical Reports.
- . Endoscopy, 45(S 02), E307-E308.
- . Oncology Reports.
- . Oncology Reports.
- . Journal of Andrology and Gynaecology, 2(3).
- . Biologics: Targets and Therapy, 39-39.
- . Oncology Reports.
- . Oncology Letters.
- . Oncology Reports.
- . Oncology Reports.
- Hypofractionated radiotherapy in invasive bladder cancer: an individual patient data meta鈥恆nalysis of the BC2001 and BCON trials. Lancet Oncology.
Chapters
- In Hussain S (Ed.), American Society Clinical Oncology Education Book
- Systematic chemotherapy for liver tumours In Fong , Poon , Tang , Dupuy & Berlin (Ed.), Hepatobiliary Cancer
- Bladder cancer, in Perez and Brady's Principles and Practice of Radiation Oncology In Halperin EC, Wazer DE, Perez CA & Brady LW (Ed.), Percy and Brady textbook of radiation oncology
- Concomitant chemo-radiotherapy principles and management In Price (Ed.), Treatment of Cancer
Conference proceedings papers
- Stratified absolute benefit with adjuvant immunotherapy (aIO) in muscle-invasive bladder cancer (MIBC): A meta-analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
- Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
- Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
- SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations. EUROPEAN UROLOGY, Vol. 85 (pp S427-S427)
- The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
- MEASURING OBJECTIVE RECOVERY OF ACTIVITY LEVELS USING WEARABLE DEVICES FOLLOWING OPEN VS INTRACORPOREAL ROBOTIC CYSTECTOMY: SECONDARY OUTCOMES ANALYSIS OF THE IROC RANDOMIZED TRIAL. JOURNAL OF UROLOGY, Vol. 209 (pp E985-E985)
- Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(16)
- Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. ANNALS OF ONCOLOGY, Vol. 33(7) (pp S1193-S1193)
- A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(17)
- RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL. JOURNAL OF UROLOGY, Vol. 207(5) (pp E695-E695)
- Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE). JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
- Outcomes of advanced plasmacytoid urothelial carcinoma receiving systemic therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
- A phase I/II feasibility study of cetuximab with 5FU and mitomycin C or cisplatin with concurrent radiotherapy in muscle invasive bladder cancer. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(6)
- Changing Landscape in the Management of Advanced Bladder Cancer. JOURNAL OF PATHOLOGY, Vol. 249 (pp S10-S10)
- . International Journal of Radiation Oncology*Biology*Physics, Vol. 105(1) (pp S138-S138)
- Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study. ANNALS OF ONCOLOGY, Vol. 30
- Difference in Acute Ischemic Post Thrombolytic Stroke Outcomes in Pre Comprehensive and Post Comprehensive Status: Single Center Experience. STROKE, Vol. 47
- . Journal of Clinical Oncology, Vol. 33(7_suppl) (pp 409-409)
- Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18)
- Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial trapeze trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
Posters
- PD42-02 RESULTS OF THE INTRACORPOREAL ROBOTIC VS OPEN CYSTECTOMY (IROC) MULTI-CENTRE RANDOMISED TRIAL.
Preprints
- Teaching interests
-
I regularly taught pharmacology to both undergraduate and postgraduate students in my previous roles and supervised both MSc and PhD students in both their projects and research. I am also:
- Deputy Lead of Urology & Renal Phase 2a MBChB
- Academic Lead for Medical Oncology Clinical Academic Training Programme.
- Professional activities and memberships
-
- Association of Cancer Physicians (ACP)
- European Society of Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- NCRI Blader & Renal Clinical studies group
- British Medical Association
- Chair of the NCRI Advanced Bladder Cancer 鈥 subgroup